Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
(2025 Dec 23)
Ann Intern Med
Colson AE, Crofoot GE, Ruane PJ, Ramgopal MN, Dretler AW, Nahass RG, Sinclair GI, Berhe M, Roberts A, Applin S, Brinson C, Jayaweera D, Workowski KA, Shihadeh F, Liu SY, Klopfer S, Llamoso C, Madera S, Dvory-Sobol H, Rhee MS, Rhee EG, Baeten JM, Eron JJ

Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis.
(2025 Oct 9)
J Infect Dis
Sesay FA, Oware K, Violette LR, Donnell D, Odoyo JB, Omollo V, Mogaka FO, McClelland RS, Balkus JE, Bukusi EA, Baeten JM, Stewart J

Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study.
(2025 Sep)
PLoS Med 22(9): e1004732
Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, Donnell D, Glidden DV, Ngure K, Brown CE, Rechkina EA, Chohan BH, Wu L, Hill E, Koome E, Akelo N, Mbaire S, Morrison SA, Kibatha M, Njeru I, Muriithi M, Coppinger C, Bushman L, Baeten JM, Anderson PL, Women Benchmark Study Team

HIV-phyloTSI: subtype-independent estimation of time since HIV-1 infection for cross-sectional measures of population incidence using deep sequence data.
(2025 Aug 14)
BMC Bioinformatics 26(1): 212
Golubchik T, Abeler-Dörner L, Hall M, Wymant C, Bonsall D, Macintyre-Cockett G, Thomson L, Baeten JM, Celum CL, Galiwango RM, Kosloff B, Limbada M, Mujugira A, Mugo NR, Gall A, Blanquart F, Bakker M, Bezemer D, Ong SH, Albert J, Bannert N, Fellay J, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Meyer L, Porter K, van Sighem A, van der Valk M, Berkhout B, Kellam P, Cornelissen M, Reiss P, Ayles H, Burns DN, Fidler S, Grabowski MK, Hayes R, Herbeck JT, Kagaayi J, Kaleebu P, Lingappa JR, Ssemwanga D, Eshleman SH, Cohen MS, Ratmann O, Laeyendecker O, Fraser C, HPTN 071 (PopART) Phylogenetics protocol team, the BEEHIVE consortium and the PANGEA consortium

Non-communicable disease (NCD) risk among people living with HIV in KwaZulu-Natal, South Africa: evidence from a randomised trial of community-based differentiated service delivery.
(2025 Jul)
J Int AIDS Soc 28 Suppl 3(Suppl 3): e26513
Sahu M, Szpiro AA, van Rooyen H, Asiimwe S, Shahmanesh M, Roberts DA, Krows ML, Sausi K, Sithole N, Schaafsma T, Baeten JM, Shapiro AE, van Heerden A, Barnabas RV